【摘要】 目的观察重组人血管内皮抑素(YH-16)+NP方案治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒副反应。方法54例晚期NSCLC随机分为治疗组和对照组,分别以YH-16+NP方案和安慰剂+NP方案治疗,治疗2周期后评价近期疗效和毒副反应。结果治疗组的有效率46.15%、临床获益率84.62%、中位肿瘤进展时间6.8个月均优于对照组的38.46%、76.92%、4.3个月,但两组比较差异无统计学意义(P>0.05)。结论YH-16+NP方案治疗晚期NSCLC疗效较好,毒副反应可耐受。更多还原

【Abstract】 Objective To investigate the short term efficacy and toxicities of recombinant human endostatin(YH-16) plus NP regimen in the treatment of non-small cell lung cancer(NSCLC).Methods 54 patients with advanced NSCLC were divided into at random two groups.The treatment group were treated by YH-16 plus NP regimen;the control group were treated by placebo plus NP regimen.The short term efficacy and toxicities were evaluated two cycles after treatment.Results The response rates of the treatment group and the control group were 46.15% and 38.46% respectively(P>0.05);the clinical benefit rates were 84.62% and 76.92% respectively(P>0.05);the median time to tumor progression were 6.9 and 4.2 months respectively(P>0.05).Conclusion YH-16 plus NP regimen is a good regimen for patients with advanced NSCLC,and the toxicities are tolerated.更多还原